Streetbeat News

Products Services

BA

The launch of Boeing's Starliner spacecraft was delayed on Saturday due to a computer system issue, minutes before takeoff.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:51 pm

BCRX

BioCryst Pharmaceuticals announced new data showing that patients with hereditary angioedema (HAE) with normal C1-inhibitor levels experienced reduced attack rates after starting ORLADEYO treatment. The data were presented at the EAACI Congress in Valencia, Spain.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:46 pm

NBTX

Nanobiotix (NASDAQ:NBTX) presented new data at ASCO 2024 from their Phase 1 Study 1100, showing promising results for their radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoint inhibitors in patients with advanced solid and metastatic tumors. The study showed a 48% ORR in anti-PD-1 naïve patients and a 28% ORR in anti-PD-1 resistant patients.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:42 pm

NTLA

Intellia Therapeutics announced that a single dose of NTLA-2002 led to a 98% mean reduction in monthly hereditary angioedema (HAE) attack rates, with an average follow-up of over 20 months. The data, presented at the EAACI Congress 2024, showed that 8 out of 10 patients remained attack-free and all patients who discontinued prophylaxis treatment remained free of chronic prophylaxis. The therapy demonstrated a favorable safety and tolerability profile.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:38 pm

GILD

RCUS

Gilead Sciences and Arcus Biosciences announced that their combination therapy significantly reduced the risk of death and disease progression in third-line metastatic colorectal cancer patients in a Phase 1b/2 trial. The results will be presented at the 2024 ASCO Annual Meeting.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:36 pm

AZN

AstraZeneca announced that its drug Imfinzi significantly reduces the risk of death by 27% compared to placebo in a global Phase III trial for limited-stage small cell lung cancer. The trial results showed a 57% survival rate at three years and will be presented at the 2024 ASCO Annual Meeting.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:16 pm

ARKB

BLK

HOOD

Cathie Wood's Ark Investment Management has withdrawn its plans for a spot-Ether ETF to focus on a spot Bitcoin ETF instead. The ARK 21Shares Bitcoin ETF ranks fourth in assets, trailing BlackRock's iShares Bitcoin Trust. The SEC has approved filings for spot-Ether ETFs, but issuers still need further approval. Ark's Bitcoin ETF saw a significant outflow recently.

Portfolio Pulse from Bibhu Pattnaik

June 02, 2024 | 2:15 pm

ALXO

ALX Oncology Holdings Inc. (NASDAQ: ALXO) presented promising Phase 1 ASPEN-07 clinical trial data at the 2024 ASCO Annual Meeting, showing tumor reduction in the majority of evaluable patients with advanced bladder cancer.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:13 pm

PBYI

Puma Biotechnology (NASDAQ:PBYI) presented findings from a Phase II study of alisertib in endocrine-resistant metastatic breast cancer at the ASCO 2024 Annual Meeting. The study showed promising clinical activity and a tolerable safety profile.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:03 pm

CLDX

Celldex Therapeutics (NASDAQ:CLDX) announced positive Phase 2 trial results for barzolvolimab, showing significant improvement in angioedema symptoms in patients with chronic spontaneous urticaria (CSU) after 12 weeks.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:01 pm